Aster DM Healthcare reports solid Q3 FY26 growth, combined proforma revenue up 15%
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
The newly certified kits are designed for early detection and large-scale screening programs
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Over 8.8?million Indians aged 60 and above currently live with dementia,
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
Subscribe To Our Newsletter & Stay Updated